Please enable Javascript
Advanced Renal Cell Carcinoma
Advertisement
TKI Continuation Versus Temporary Treatment Cessation in Advanced Clear Cell RCC
Emily Menendez
Advanced Renal Cell Carcinoma
|
March 17, 2023
Patients with accRCC were assigned to receive either a conventional continuation strategy or a drug-free interval strategy.
Read More
Utilizing Plasma and Urine Free Glycosaminoglycans as Biomarkers in mRCC
Emily Menendez
Advanced Renal Cell Carcinoma
|
March 10, 2023
Plasma and urine free glycosaminoglycan profiles—or GAGomes—can potentially be used as metabolic biomarkers for mRCC.
Read More
Dr. Rana McKay on Radiation Therapy and Radiopharmaceuticals for RCC
Rana McKay, MD
Advanced Renal Cell Carcinoma
|
March 8, 2023
Dr. McKay explains how radiation therapy and modalities fit into the treatment paradigm for RCC.
View More
Dr. Rana McKay on Novel Therapies and Sequences for Metastatic RCC Treatment
Rana McKay, MD
Advanced Renal Cell Carcinoma
|
March 8, 2023
Dr. McKay summarizes the novel therapies or optimal sequencing patterns that are close to entering the mRCC treatment space.
View More
Dr. Rana McKay on Second-line Therapy and Beyond for Metastatic RCC
Rana McKay, MD
Advanced Renal Cell Carcinoma
|
March 8, 2023
Dr. McKay offers an overview of the second-line and later-line therapy options after progression for metastatic RCC.
View More
Dr. Rana McKay on Frontline Immunotherapy for Metastatic RCC
Rana McKay, MD
Advanced Renal Cell Carcinoma
|
March 8, 2023
Dr. McKay highlights the results of a few studies that support the use of frontline immunotherapy for favorable-risk mRCC.
View More
Dr. Rana McKay on the Current Treatment Paradigm for Metastatic RCC
Rana McKay, MD
Advanced Renal Cell Carcinoma
|
March 8, 2023
Dr. Rana McKay details how advanced or mRCC is currently managed and how the treatment paradigm has evolved since 2018.
View More
HCRN GU16-260: Nivolumab, Salvage Nivo/Ipi in Advanced Clear Cell RCC
Michael B. Atkins, MD
ASCO GU Symposium 2023
|
February 18, 2023
Michael Atkins, MD, discusses TFS outcomes from the phase II study and argues for immunotherapy in favorable-risk patients.
View More
Nivolumab and Salvage Nivolumab Plus Ipilimumab for aRCC: Outcomes From a Phase 2 Study
Emily Menendez
ASCO GU Symposium 2023
|
February 17, 2023
Researchers assessed TFS outcomes from HCRN GU16-260, investigating nivolumab and salvage nivolumab plus ipilimumab for aRCC.
Read More
BIONIKK Trial: Second-line Efficacy, Survival Results
Zachary Bessette
ASCO GU Symposium 2023
|
February 17, 2023
Updated OS and efficacy results of second-line treatment in patients with mRCC treated in the BIONIKK trial were presented.
Read More
Ethnicity-Based Outcomes for Patients With mRCC Treated With Nivolumab, Ipilimumab Combo
Zachary Bessette
ASCO GU Symposium 2023
|
February 17, 2023
Latinx patients with mRCC demonstrated shorter PFS after nivolumab-plus-ipilimumab treatment at a tertiary care center.
Read More
Real-world Outcomes of Avelumab Plus Axitinib in Advanced RCC
Zachary Bessette
ASCO GU Symposium 2023
|
February 17, 2023
A 24-month analysis highlighted OS, PFS, ORR, and best response to avelumab-plus-axitinib treatment in patients with aRCC.
Read More
Systemic Treatment for Recurrent RCC
Tian Zhang, MD
ASCO GU Symposium 2023
|
February 16, 2023
Tian Zhang, MD, describes the current standard-of care treatment approach for metastatic RCC, including second-line therapy.
View More
Harnessing the Potential of Immunotherapy, Optimal Sequencing in Advanced RCC
David Braun, MD, PhD
Advanced Renal Cell Carcinoma
|
February 14, 2023
David Braun, MD, PhD, highlights the available later-line therapy options for RCC, how the therapies are sequenced, and more.
Read More
Pembrolizumab/Axitinib Combination for mRCC in Further-Line Treatment
Emily Menendez
Advanced Renal Cell Carcinoma
|
February 3, 2023
Pembrolizumab/axitinib is a common first-line mRCC treatment, but its use in later lines of therapy has not been researched.
Read More
Comparing the Cost-Effectiveness of Treatments for mRCC
Emily Menendez
Advanced Renal Cell Carcinoma
|
January 25, 2023
Researchers performed a cost-effectiveness analysis of sunitinib and 6 immunotherapy-TKI/immunotherapy drug combinations.
Read More
ASCO Guideline Authors Offer Advice for Managing Metastatic Clear Cell RCC
Zachary Bessette
Advanced Renal Cell Carcinoma
|
January 5, 2023
Three of the guideline authors offered additional information on cytoreductive nephrectomy and systemic treatment.
Read More
Evaluating Renal Mass Biopsy and Nephrectomy in Small Renal Masses
Robert Dillard
IKCS 2022
|
December 18, 2022
A study evaluated how accurately prospectively collected renal mass biopsy can identify DNA mutations in nephrectomy.
Read More
The Gut Microbiome Plays a Role in Metastatic Kidney Cancer
Robert Dillard
IKCS 2022
|
December 18, 2022
Gut bacteria play a role in the development of sarcopenia in metastatic renal cell carcinoma.
Read More
Assessing AUA Surveillance Guidelines in Kidney Cancer
Robert Dillard
IKCS 2022
|
December 18, 2022
Following AUA guidelines may increase survival in kidney cancer.
Read More
Load More
Advertisement
Advertisement
Advertisement